Table 1.
Ref. | Treatment | Results |
Arora et al[56] | Thiamine | Improved endothelial-dependent vasodilation in subjects with impaired glucose tolerance and in T2DM patients |
Du et al[57] | Benfotiamine + α-lipoic acid | Normalization of AGEs production and prostacyclin synthase activity and decreases hexosamine-modified protein in monocytes without changing glycaemic control in T1DM |
González-Ortiz et al[58] | Thiamine | Lower blood glucose and leptin in T2DM patients |
Polizzi et al[59] | Thiamine + vitamin B6 | Administration of vitamin B6 together with thiamine but not B6 itself decreases DNA glycation in T2DM |
Riaz et al[60] | Thiamine | Decreased albumin in urine in T2DM patients |
Schupp et al[61] | Benfotiamine | Decreased genomic damage in peripheral lymphocytes in haemodialysis patients |
Stirban et al[62] | Benfotiamine | No effect on skin autofluorescence in T2DM patients |
Stirban et al[63] | Benfotiamine | No effect on flow-mediated dilation in T2DM patients |
T1DM: Type 1 diabetes mellitus; AGEs: Advanced glycation end products; T2DM: Type 2 diabetes mellitus.